HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>As one of the few companies in the world that could provide one-stop solutions including all major medical devices used in non-vascular interventional surgery, Innovex’s outlook is promising.</li>
<li>About 30% overseas revenue indicates that the Company’s internationalization is on track, which could help to "hedge" negative domestic policy risks.</li>
<li>In terms of the valuation, Innovex’s valuation should be higher than Scivita but lower than Aohua. However, Innovex has the potential to surpass Aohua in the future.</li>
</ul>


As one of the few companies in the world that could provide one-stop solutions including all major medical devices used in non-vascular interventional surgery, Innovex’s outlook is promising.
About 30% overseas revenue indicates that the Company’s internationalization is on track, which could help to "hedge" negative domestic policy risks.
In terms of the valuation, Innovex’s valuation should be higher than Scivita but lower than Aohua. However, Innovex has the potential to surpass Aohua in the future.


Pre-IPO Innovex Medical - A Comprehensive Product Portfolio Underpins Future Growth Prospects

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innovex Medical (IVM HK)

Pre-IPO Innovex Medical - A Comprehensive Product Portfolio Underpins Future Growth Prospects

Innovex’s outlook is promising due to its capability to provide one-stop solutions. Its internationalization is on track to hedge domestic policy...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)